Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 10/20 | 0.41 |
| ▸ | RXRA | P19793 | 9/20 | 0.41 |
| ▸ | RXRG | P48443 | 8/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394063 | 0.81 | POLB (0.44) | RXRBRXRARXRGDHODHPPARG | |
| SCHEMBL5397848 | 0.81 | THRB (0.45) | RAB9A | |
| SCHEMBL5833502 | 0.77 | RXRA (0.49) | RXRBRXRARXRGPPARGPPARD | |
| SCHEMBL25732360 | 0.71 | RXRB (0.49) | RXRBRXRARXRGPPARGPPARD | |
| SCHEMBL5392057 | 0.71 | FFAR1 (0.39) | RXRBRXRARXRG | |
| SCHEMBL5397938 | 0.71 | NPC1 (0.35) | RXRBRXRARXRGRAB9A | |
| SCHEMBL16347731 | 0.71 | RAB9A (0.46) | RXRBRXRARXRGHTR2AHTR2C | |
| SCHEMBL646805 | 0.71 | ALDH1A1 (0.51) | RXRBRXRARXRGDHODHSMN1; SMN2 | |
| SCHEMBL5408088 | 0.70 | ALDH1A1 (0.37) | RXRBRXRARXRGRAB9AMRGPRX4 | |
| SCHEMBL5400955 | 0.70 | CA9 (0.41) | RXRBRXRARXRGSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230031-B2 | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-20050085541-A1 | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1471049-A1 | NOVEL THYROID HORMONE RECEPTOR LIGAND, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085541-A1 | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | TSHR, THRA, THRB | RXRB 67/4885RXRA 57/4885RXRG 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.